Resistance to thyroid hormone (RTH) is usually dominantly inherited an
d is characterized by elevated free thyroid hormones in the serum and
failure to suppress pituitary thyroid stimulating hormone (TSH) secret
ion with variable refractoriness to hormone action in peripheral tissu
es. Two major forms of the disorder are recognized: asymptomatic indiv
iduals with generalized resistance (GRTH) and patients with thyrotoxic
features, suggesting predominant pituitary resistance (PRTH). Molecul
ar genetic analyses indicate that both GRTH and PRTH are associated wi
th diverse mutations in the thyroid hormone receptor beta gene, which
localize to three regions in the hormone binding domain of the recepto
r. In addition to being functionally impaired, the mutant receptors ar
e also able to inhibit their wild-type counterparts in a dominant nega
tive manner. Recognized features of RTH include failure to thrive, gro
wth retardation and attention-deficit hyperactivity disorder in childh
ood, and goitre and thyrotoxic cardiac symptoms in adults. The pathoge
nesis of variable tissue resistance is not fully understood but may be
related to the differing tissue distributions of a and b thyroid horm
one receptors and variable dominant negative activity of mutant recept
ors on different target genes.